News

SWOG Front Line banner
The Front Line
Jul 22, 2022

The SWOG Latin America Initiative

SWOG Front Line banner
The Front Line
Jul 15, 2022

A Tenth Year of Blogging

SWOG Front Line banner
The Front Line
Jul 8, 2022

SWOG Will Expand Phase II Accrual Monitoring

SWOG Front Line banner
The Front Line
Jul 1, 2022

VA Storefront Program: Our Trials to More VAs

New VA Storefront Support Program: Bringing trials to even more VAs
SWOG Front Line banner
The Front Line
Jun 24, 2022

Improving Patient Advocacy - At NCI & SWOG

SWOG Front Line banner
The Front Line
Jun 17, 2022

Time to Think About SWOG’s Next Chair (!)

SWOG Latin America Initiative Newsletter
Announcement
Jun 17, 2022

SWOG Latin America Initiative News: Summ 2022

The first issue of the SWOG Latin America Initiative (SLAI) Newsletter is out!
SWOG Front Line banner
The Front Line
Jun 3, 2022

Previews of Our Next Best of SWOG Webinar

S0931 EVEREST results at ASCO 2022
Press Release
Jun 3, 2022

Adjuvant Everolimus Benefit in High-Risk RCC

S0931 found everolimus after surgery tended to increase recurrence-free survival time in patients with high-risk kidney cancer, although results narrowly missed reaching statistical significance